Southern Illinois University School of Medicine researchers are enrolling patients in a new oral medication study for psoriasis. The POETYK PsO study will give participants the opportunity to try a new investigational drug designed to block a protein called TYK2 within their immune system. The randomized clinical trial could lead to long-term relief of symptoms.
Dr. Stephen Stone, professor of internal medicine at SIU School of Medicine, will serve as the primary investigator on the study. He is director of clinical research for dermatology and specializes in acne, psoriasis and skin cancer.
If you have stable, moderate-to-severe plaque psoriasis and are at least 18 years old, you may qualify for this study. For information, contact Vineela Sunkepalli at (217) 545-7321 or visit clinicaltrials.gov.